Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. Debarri H, et al. Among authors: castaigne s. Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645. Oncotarget. 2015. PMID: 26486081 Free PMC article.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C. Boissel N, et al. Among authors: castaigne s. J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625116
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Renneville A, et al. Among authors: castaigne s. Oncotarget. 2014 Feb 28;5(4):916-32. doi: 10.18632/oncotarget.1536. Oncotarget. 2014. PMID: 24659740 Free PMC article. Clinical Trial.
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Micol JB, et al. Among authors: castaigne s. Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27. Blood. 2014. PMID: 24973361 Free PMC article. Clinical Trial.
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. Lambert J, et al. Among authors: castaigne s. Oncotarget. 2014 Aug 15;5(15):6280-8. doi: 10.18632/oncotarget.2196. Oncotarget. 2014. PMID: 25026287 Free PMC article. Clinical Trial.
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A. Ferret Y, et al. Among authors: castaigne s. Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22. Haematologica. 2018. PMID: 29472349 Free PMC article.
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N. Fenwarth L, et al. Among authors: castaigne s. Int J Mol Sci. 2020 Aug 6;21(16):5626. doi: 10.3390/ijms21165626. Int J Mol Sci. 2020. PMID: 32781546 Free PMC article. Review.
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.
Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A, Clappier E, Hayette S, Récher C, Raffoux E, Pigneux A, Berthon C, Terré C, Celli-Lebras K, Castaigne S, Boissel N, Rousselot P, Preudhomme C, Dombret H, Duployez N. Lambert J, et al. Among authors: castaigne s. Blood Adv. 2021 Dec 14;5(23):5258-5268. doi: 10.1182/bloodadvances.2021004322. Blood Adv. 2021. PMID: 34625784 Free PMC article. Clinical Trial.
200 results